688189 南新制药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-7.615-31.865-0.830-5.823-10.832
总资产报酬率 ROA (%)-6.084-24.264-0.592-3.859-7.678
投入资产回报率 ROIC (%)-6.309-25.479-0.618-4.094-8.237

边际利润分析
销售毛利率 (%)33.43954.59184.47585.78887.125
营业利润率 (%)-91.343-147.393-1.296-10.512-28.852
息税前利润/营业总收入 (%)-92.684-148.165-0.576-9.810-28.734
净利润/营业总收入 (%)-91.128-150.891-1.499-13.968-24.539

收益指标分析
经营活动净收益/利润总额(%)73.29616.838-1,042.214-52.66046.545
价值变动净收益/利润总额(%)5.7360.000163.1597.610-1.551
营业外收支净额/利润总额(%)0.2130.148-2.1340.7390.105

偿债能力分析
流动比率 (X)2.4992.2902.9712.3082.391
速动比率 (X)2.2922.1102.9002.2662.300
资产负债率 (%)22.56828.15125.23033.67634.582
带息债务/全部投入资本 (%)14.51218.78420.31829.32128.971
股东权益/带息债务 (%)586.610430.395390.453239.254243.183
股东权益/负债合计 (%)371.147272.160300.481199.680189.065
利息保障倍数 (X)80.909267.428-0.831-12.573-194.419

营运能力分析
应收账款周转天数 (天)419.158489.690312.189339.743297.907
存货周转天数 (天)265.166137.81092.393160.282215.745